Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Fighting disease deep inside the brain

18.02.2013
Some 90,000 patients per year are treated for Parkinson's disease, a number that is expected to rise by 25 percent annually.
Deep Brain Stimulation (DBS), which consists of electrically stimulating the central or peripheral nervous system, is currently standard practice for treating Parkinson's, but it can involve long, expensive surgeries with dramatic side effects. Miniature, ultra-flexible electrodes developed in Switzerland, however, could be the answer to more successful treatment for this and a host of other health issues.

Today, Professor Philippe Renaud of the École Polytechnique Fédérale de Lausanne (EPFL) in Switzerland reports on soft arrays of miniature electrodes developed in his Microsystems Laboratory that open new possibilities for more accurate and local DBS. At the 2013 Annual Meeting of the American Association for the Advancement of Science (AAAS) in Boston, in a symposium called "Engineering the Nervous System: Solutions to Restore Sight, Hearing, and Mobility," he announces the start of clinical trials and early, yet promising results in patients, and describes new developments in ultra-flexible electronics that can conform to the contours of the brainstem—in the brain itself—for treating other disorders.

At AAAS, Renaud outlines the technology behind these novel electronic interfaces with the nervous system, the associated challenges, and their immense potential to enhance DBS and treat disease, even how ultra flexible electronics could lead to the auditory implants of the future and the restoration of hearing. "Although Deep Brain Stimulation has been used for the past two decades, we see little progress in its clinical outcomes," Renaud says. "Microelectrodes have the potential to open new therapeutic routes, with more efficiency and fewer side effects through a much better and finer control of electrical activation zones." The preliminary clinical trials related to this research are being done in conjunction with EPFL spin-off company Aleva Neurotherapeutics, the first company in the world to introduce microelectrodes in Deep Brain Stimulation leading to more precise directional stimulation.
Researcher Contact:
Professor Philippe Renaud
philippe.renaud@epfl.ch
Microsystems Laboratory 4 : http://lmis4.epfl.ch/
Press Kit: http://bit.ly/VJtgH5
About EPFL:
With over 350 laboratories and research groups on campus, EPFL is one of Europe's most innovative and productive scientific institutions. Ranked top 3 in Europe and top 20 worldwide in many scientific rankings, EPFL has attracted the best researchers in their fields.

The institute's unique structure fosters trans-disciplinary research and promotes partnerships with other institutions. It continuously combines fundamental research and engineering. http://information.epfl.ch/glance

Hillary Sanctuary | EurekAlert!
Further information:
http://www.epfl.ch

More articles from Medical Engineering:

nachricht First brain images of African infants enable research into cognitive effects of nutrition
22.04.2014 | University College London

nachricht Key milestone for brown fat research with a ground-breaking MRI scan
17.04.2014 | University of Warwick

All articles from Medical Engineering >>>

The most recent press releases about innovation >>>

Anzeige

Anzeige

Event News

Siemens at the 2014 UIC ERTMS World Conference in Istanbul

01.04.2014 | Event News

AERA Meeting: German and US-American educational researchers in dialogue

28.03.2014 | Event News

WHS Regional Meeting: International experts address health challenges in Latin America

24.03.2014 | Event News

 
Latest News

Pilot study suggests ways to widen access to fecal transplants for C. diff infections

24.04.2014 | Health and Medicine

WSU innovation improves drowsy driver detection

24.04.2014 | Automotive Engineering

Building Stronger Bridges

23.04.2014 | Architecture and Construction

VideoLinks
B2B-VideoLinks
More VideoLinks >>>